OverviewSuggest Edit

Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. Its products are based on a barrier technology that includes marine enzymes. The company has three models for sales of its products: mouth spray as a medical device, mouth spray as a cosmetic product and an enzyme formulation that is included in its customers' skincare products.

TypePublic
Founded2007
HQLund, SE
Websiteenzymatica.se

Latest Updates

Employees (est.) (Sept 2021)27(+59%)
Revenue (FY, 2021)KR57.2 M(-48%)
Share Price (May 2022)KR5(-3%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Enzymatica

Claus Egstrand

Claus Egstrand

Chief Operating Officer
Ulf Blom

Ulf Blom

Co-founder of Enzymatica AB & Director of Innovation & Pipeline
Kristoffer Ahlerup

Kristoffer Ahlerup

Commercial Director
Asa Anderlind

Asa Anderlind

Director of Quality Assurance
Johan Lindvall

Johan Lindvall

CTO, EVP
Gudmundur Palmason

Gudmundur Palmason

Director
Show more

Enzymatica Office Locations

Enzymatica has offices in Lund and Reykjavík
Lund, SE (HQ)
Scheelevägen 17
Reykjavík, IS
Fiskislóð 39
Show all (2)

Enzymatica Financials and Metrics

Enzymatica Revenue

Enzymatica's revenue was reported to be kr57.24 m in FY, 2021
SEK

Revenue (FY, 2021)

57.2m

Gross profit (FY, 2021)

35.7m

Net income (FY, 2021)

(45.4m)

EBITDA (FY, 2021)

(45.2m)

EBIT (FY, 2021)

(45.2m)

Market capitalization (6-May-2022)

746.6m

Closing stock price (6-May-2022)

5.0

Cash (31-Dec-2021)

31.6m

EV

717.6m
Enzymatica's current market capitalization is kr746.6 m.
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

52.6m61.3m111.2m57.2m

Cost of goods sold

(10.3m)(10.9m)(29.5m)(23.9m)

Gross profit

43.5m51.5m82.8m35.7m

R&D expense

(20.1m)(26.9m)(22.4m)(24.2m)
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Revenue

13.3m6.4m19.5m26.8m13.9m28.3m23.1m38.5m

Cost of goods sold

(3.5m)(2.4m)(5.3m)(5.8m)(5.9m)(7.2m)(12.2m)(17.8m)

Gross profit

10.0m4.2m14.5m21.2m8.3m21.2m11.3m21.7m

R&D expense

(6.2m)(8.9m)(7.2m)(4.1m)(5.7m)(6.4m)(12.3m)(15.9m)
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Cash

70.3m29.3m24.0m31.6m

Accounts Receivable

10.4m15.3m32.8m16.3m

Prepaid Expenses

3.1m3.1m4.1m

Inventories

5.6m7.0m10.5m12.4m
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Cash

53.9m40.8m30.7m33.9m30.9m33.7m64.8m50.0m

Accounts Receivable

10.1m5.0m16.0m24.4m11.2m12.7m3.1m10.6m

Inventories

7.0m7.1m5.7m7.6m9.9m9.6m14.0m13.5m
Annual
SEKFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(40.6m)(41.7m)(12.1m)(45.2m)

Depreciation and Amortization

6.2m7.1m6.2m

Inventories

(2.9m)(1.4m)(4.0m)
Quarterly
SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021

Net Income

(11.9m)(27.5m)(34.6m)220.0k(11.7m)(13.9m)(28.7m)(34.7m)
SEKFY, 2018

Revenue/Employee

2.5m
Show all financial metrics

Enzymatica Operating Metrics

Aug, 2019Oct, 2019

Enrollment Participants (ColdZyme, Germany)

701

Study Centres (ColdZyme, Germany)

10

Enrollment Participants (ColdZyme, Iceland)

45

Study Centres (ColdZyme, Iceland)

1
Show all operating metrics

Enzymatica Acquisitions / Subsidiaries

Company NameDateDeal Size
Zymetech ehfJanuary 28, 2016
Enzymatica Care AB
Enzymatica North America Inc

Enzymatica Revenue Breakdown

Embed Graph

Enzymatica revenue breakdown by business segment: 100.0% from MEDICAL DEVICES

Human Capital Metrics

Enzymatica's employees are reported to be approximately 53% female and 47% male.
Embed Graph
Show all human capital metrics

Enzymatica Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Enzymatica Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Enzymatica Online and Social Media Presence

Embed Graph

Enzymatica News and Updates

Enzymatica AB: Continued lower sales due to pandemic but some stabilization

STOCKHOLM, July 16, 2021 /PRNewswire/ -- Q2 Net sales reached SEK 6.1 (13.9) million. Result after tax came in at SEK -19.7 (-11.7) million. Earnings per share, basic and diluted, were SEK -0.14 (-0.08). Cash and cash equivalents were SEK 64.8 (30.9) million. Significant events in Q1...

Claus Egstrand appointed new CEO of Enzymatica

STOCKHOLM, July 13, 2021 /PRNewswire/ -- The Board of Directors of Enzymatica has appointed Claus Egstrand, the company's Chief Operating Officer, as CEO of Enzymatica. Claus Egstrand assumes his new position at the latest on January 1, 2022 and succeeds acting CEO Therese Filmersson, who...

Enzymatica shares jump as company says mouth spray can deactivate COVID-19

Shares of Enzymatica jumped 67% in Stockholm as the company said preliminary results show the ability of the mouth spray ColdZyme, in vitro, to deactivate SARS-CoV-2, the virus causing the COVID-19 pandemic. The study demonstrated that ColdZyme deactivates SARS-CoV-2 coronavirus by 98.3%, the compa…
Show more

Enzymatica Frequently Asked Questions

  • When was Enzymatica founded?

    Enzymatica was founded in 2007.

  • Who are Enzymatica key executives?

    Enzymatica's key executives are Claus Egstrand, Ulf Blom and Kristoffer Ahlerup.

  • How many employees does Enzymatica have?

    Enzymatica has 27 employees.

  • What is Enzymatica revenue?

    Latest Enzymatica annual revenue is kr57.2 m.

  • What is Enzymatica revenue per employee?

    Latest Enzymatica revenue per employee is kr2.1 m.

  • Who are Enzymatica competitors?

    Competitors of Enzymatica include Bactiguard, Karo Pharma and Casada.

  • Where is Enzymatica headquarters?

    Enzymatica headquarters is located at Scheelevägen 17, Lund.

  • Where are Enzymatica offices?

    Enzymatica has offices in Lund and Reykjavík.

  • How many offices does Enzymatica have?

    Enzymatica has 2 offices.